MetLife Investment Management’s Viridian Therapeutics VRDN Stock Holding History

MetLife Investment Management’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$968K	Sell	52,709 -655,818	-93%	-$10.6M	﹤0.01%	1543
2026 Q1	$13.9M	Buy	708,527 +664,542	+1,511%	+$19.7M	0.07%	272
2025 Q4	$1.37M	Buy	43,985 +356	+0.8%	+$9.76K	0.01%	1261
2025 Q3	$942K	Hold	43,629	–	–	﹤0.01%	1482
2025 Q2	$610K	Hold	43,629	–	–	﹤0.01%	1590
2025 Q1	$588K	Sell	43,629 -666	-2%	-$11.3K	﹤0.01%	1641
2024 Q4	$849K	Buy	44,295 +7,914	+22%	+$172K	﹤0.01%	1504
2024 Q3	$828K	Hold	36,381	–	–	﹤0.01%	1497
2024 Q2	$473K	Buy	36,381 +10,811	+42%	+$150K	﹤0.01%	1743
2024 Q1	$448K	Buy	25,570 +3,299	+15%	+$64K	﹤0.01%	1736
2023 Q4	$485K	Hold	22,271	–	–	﹤0.01%	1701
2023 Q3	$342K	Hold	22,271	–	–	﹤0.01%	1859
2023 Q2	$530K	Buy	22,271 +2,428	+12%	+$62.3K	﹤0.01%	1660
2023 Q1	$505K	Hold	19,843	–	–	﹤0.01%	1637
2022 Q4	$580K	Buy	19,843 +6,129	+45%	+$141K	﹤0.01%	1545
2022 Q3	$281K	Hold	13,714	–	–	﹤0.01%	2070
2022 Q2	$159K	Buy	+13,714	New	+$184K	﹤0.01%	2458

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

MetLife Investment Management's VRDN Position: Q2 2026 in Review

MetLife Investment Management reduced its Viridian Therapeutics (VRDN) stake by 93% in Q2 2026, selling an estimated $10.6M and leaving 52,709 shares worth $968K. The position accounts for ﹤0.01% of the portfolio, ranked #1543.

MetLife Investment Management first reported a position in VRDN in Q2 2022 and has held it in 17 quarters since. The position peaked at $13.9M in Q1 2026. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

MetLife Investment Management held 52,709 shares of Viridian Therapeutics worth $968K as of Q2 2026.
MetLife Investment Management sold 655,818 Viridian Therapeutics shares in Q2 2026, an estimated $10.6M.
Viridian Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1543 holding.
MetLife Investment Management first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 17 quarters since.
MetLife Investment Management's Viridian Therapeutics position peaked at $13.9M in Q1 2026.
214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.